A Phase 3 interventional study of Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) in Macular Degeneration, sponsored by Bayer. Completed at 71 sites in 14 countries. Open to participants aged 51 Years and older. Per ClinicalTrials.gov, last updated 2021-06-11.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.
Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 11th largest by enrollment, is one of 6 that started in 2015, is one of 18 in phase 3, and was the 36th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Czechia, Hungary and 6 more countries
Ages 50+
Tianjin Medical University Eye Hospital
Ages 50–85
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 51 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 19 · Phase 4 27
First in 2005; this study’s year is marked. 6 started in 2015.
This study's enrollment of 336 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 66 interventional studies. Of the 48 that completed or were terminated, 28 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 66 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
30 studies in Macular Degeneration by Bayer: none open now, 1 under way, none of them phase 3. Of 29 finished, 10 (34%) have results posted.
Among the 30 studies in Macular Degeneration by Bayer, this one is the 3rd largest by enrollment of the 10 interventional ones that give a count, is one of 4 that started in 2015, is one of 4 in phase 3, and was the 14th registered.
Bayer’s Macular Degeneration studies by the year they started, since 2008.
2 of the studies testing aflibercept in Macular Degeneration that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
| NCT04932980Berner AugenklinikComparison of Rapid Aflibercept and Brolucizumab T&E in wAMD | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 66 studies testing aflibercept in Macular Degeneration, from their registry updates:
Among Bayer’s 30 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
To compare the efficacy of 2 mg aflibercept administered by two different intravitreal (IVT) treatment regimens to subjects with neovascular age-related macular degeneration (nAMD)
330 Patients who have completed at least one year of treatment with aflibercept will be randomized to two different aflibercept regimens and followed for 76 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The following criteria must have been met at the initial start of aflibercept treatment (i.e. start of aflibercept treatment at least 1 year before this study):
The subject's history of aflibercept treatment meets ALL of the following:
Exclusion Criteria:
Subretinal hemorrhage that was:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aflibercept was administered 2mg per injection intravitreal (IVT) in the study eye in Aflibercept extended dosing. Flexible dosing interval is ≥ 8 weeks (no upper limit) based on visual and anatomic outcomes as judged by the investigator. When/if visual and anatomical outcomes indicated that the disease had re-activated, the treatment interval reverted to the last treatment interval in which the disease was inactive (ie, no signs of exudation were observed).
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Aflibercept was administered 2mg per injection IVT in the study eye in Aflibercept 2Q8. Fixed dosing interval is 8 weeks (±3 days), modification of the treatment interval was not allowed.
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
A dose of 2 mg aflibercept injected intravitreally
Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) Letter Score for the Study Eye
Visual function was assessed with the procedure from the ETDRS adapted for the Age Related Eye Disease Study using charts with 70 letters at a starting distance of 4 meters. Charts are organized in 14 lines of decreasing size with 5 letters each. Participants reading up to 19 letters at 4 meters were tested at 1 meter to read the first 6 lines. The score equals the sum of letters read at 1 meter and 4 meters. If more than 19 letters are read at 4 meters the score equals the number of letters read plus 30. The score range is 0 to 100, and a higher score represents better visual function.
Time frame: From baseline to Week 52
Percentage of Participants Maintaining Vision in the Study Eye
A participant was classified as maintaining vision if the participant had lost fewer than 15 letters in the ETDRS letter score compared to baseline.
Time frame: At week 52
Percentage of Participants Who Gained From Baseline 5 or More Letters in the Study Eye
Time frame: At week 52
Mean Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye
Retinal characteristic was evaluated using Optical coherence tomography (OCT).
Time frame: From baseline to week 52
Mean Change From Baseline in Choroidal Neovascularization (CNV) Area in the Study Eye
Choroidal neovascularization measured by optical coherence tomography (OCT).
Time frame: From baseline to week 52
Percentage of Participants Who Lost From Baseline 30 or More Letters in the Study Eye
Time frame: At week 52
Mean Change From Baseline in Total Score for National Eye Institute 25-Item Visual Function (NEI VFQ-25) Questionnaire
National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ-25) total score ranges from 0 to 100, where 100 represents the best possible score and 0 represents the worst.
Time frame: From baseline to week 52
Number of Participants With Treatment-emergent Adverse Events (TEAE)
Time frame: Started after the first application of aflibercept in the study and less than or equal to 30 days after the last dose of study drug over approximately 1.5 years
Study was conducted at 76 centers in 14 countries or regions, between 29-SEP-2015 (first participant first visit) and 04-JUN-2020 (last participant last visit)
| Milestone | Aflibercept Extended Dosing | Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) |
|---|---|---|
| Started | 168 | 168 |
| Treated | 167 | 168 |
| Post-baseline bcva assessment | 165 | 167 |
| Completed | 149 | 154 |
| Not completed | 19 | 14 |
| Withdrew: Physician decision | 3 | 1 |
| Withdrew: Withdrawal by subject | 6 | 5 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Adverse event | 4 | 2 |
| Withdrew: Death | 0 | 3 |
| Withdrew: Treatment failure | 1 | 0 |
| Withdrew: Other reason | 4 | 2 |
Visual function was assessed with the procedure from the ETDRS adapted for the Age Related Eye Disease Study using charts with 70 letters at a starting distance of 4 meters. Charts are organized in 14 lines of decreasing size with 5 letters each. Participants reading up to 19 letters at 4 meters were tested at 1 meter to read the first 6 lines. The score equals the sum of letters read at 1 meter and 4 meters. If more than 19 letters are read at 4 meters the score equals the number of letters read plus 30. The score range is 0 to 100, and a higher score represents better visual function.
| Letters read correctly | Aflibercept Extended Dosing | Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) |
|---|---|---|
| Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) Letter Score for the Study Eye | -0.3 ± 7.5 | -0.5 ± 8.4 |
A participant was classified as maintaining vision if the participant had lost fewer than 15 letters in the ETDRS letter score compared to baseline.
| Percentage of participants | Aflibercept Extended Dosing | Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) |
|---|---|---|
| Percentage of Participants Maintaining Vision in the Study Eye | 95.2 | 94.0 |
| Percentage of participants | Aflibercept Extended Dosing | Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) |
|---|---|---|
| Percentage of Participants Who Gained From Baseline 5 or More Letters in the Study Eye | 24.2 | 21.0 |
Retinal characteristic was evaluated using Optical coherence tomography (OCT).
| μm | Aflibercept Extended Dosing | Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) |
|---|---|---|
| Mean Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye | -24.4 ± 55.2 | -33.4 ± 47.1 |
Choroidal neovascularization measured by optical coherence tomography (OCT).
| mm*2 | Aflibercept Extended Dosing | Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) |
|---|---|---|
| Mean Change From Baseline in Choroidal Neovascularization (CNV) Area in the Study Eye | 0.274 ± 2.723 | 0.204 ± 2.813 |
| Percentage of participants | Aflibercept Extended Dosing | Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) |
|---|---|---|
| Percentage of Participants Who Lost From Baseline 30 or More Letters in the Study Eye | 0 | 0.6 |
National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ-25) total score ranges from 0 to 100, where 100 represents the best possible score and 0 represents the worst.
| Score on a scale | Aflibercept Extended Dosing | Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) |
|---|---|---|
| Mean Change From Baseline in Total Score for National Eye Institute 25-Item Visual Function (NEI VFQ-25) Questionnaire | 0.186 ± 9.601 | -1.694 ± 10.328 |
| Participants | Aflibercept Extended Dosing | Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) |
|---|---|---|
| Any TEAE | 130 | 124 |
| Any serious TEAE | 26 | 23 |
Collected over From after the first application of aflibercept in the study to 30 days after the last dose of study drug over approximately 1.5 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aflibercept Extended Dosing | 0/167 (0%) | 26/167 (15.6%) | 60/167 (35.9%) |
| Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) | 3/168 (1.8%) | 23/168 (13.7%) | 70/168 (41.7%) |
| Event | Aflibercept Extended Dosing | Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) |
|---|---|---|
| Myocardial infarctionCardiac disorders | 3/167 | 0/168 |
| FallInjury, poisoning and procedural complications | 3/167 | 0/168 |
| Atrial fibrillationCardiac disorders | 2/167 | 1/168 |
| Retinal haemorrhageEye disorders | 2/167 | 0/168 |
| PneumoniaInfections and infestations | 2/167 | 0/168 |
| Humerus fractureInjury, poisoning and procedural complications | 2/167 | 1/168 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/167 | 2/168 |
| Transient ischaemic attackNervous system disorders | 0/167 | 2/168 |
| Acute myocardial infarctionCardiac disorders | 1/167 | 0/168 |
| BradycardiaCardiac disorders | 1/167 | 0/168 |
| Event | Aflibercept Extended Dosing | Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) |
|---|---|---|
| CataractEye disorders | 17/167 | 19/168 |
| Visual acuity reducedEye disorders | 14/167 | 4/168 |
| Subretinal fluidEye disorders | 14/167 | 14/168 |
| NasopharyngitisInfections and infestations | 4/167 | 12/168 |
| Intraocular pressure increasedInvestigations | 7/167 | 11/168 |
| Neovascular age-related macular degenerationEye disorders | 8/167 | 10/168 |
| Choroidal neovascularisationEye disorders | 9/167 | 9/168 |
| InfluenzaInfections and infestations | 9/167 | 9/168 |
Safety analysis set (SAF): included all participants who received any study drug
| Age, Continuous(years) | Aflibercept Extended Dosing | Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) | Total |
|---|---|---|---|
| Mean | 76.3 ± 8.3 | 74.7 ± 7.0 | 75.5 ± 7.7 |
| Sex: Female, Male(Participants) | Aflibercept Extended Dosing | Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) | Total |
|---|---|---|---|
| Female | 107 | 108 | 215 |
| Male | 60 | 60 | 120 |
| Ethnicity (NIH/OMB)(Participants) | Aflibercept Extended Dosing | Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 136 | 128 | 264 |
| Unknown or Not Reported | 31 | 40 | 71 |
| Race (NIH/OMB)(Participants) | Aflibercept Extended Dosing | Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 139 | 132 | 271 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 28 | 36 | 64 |
| Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual(Letters read correctly) | Aflibercept Extended Dosing | Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) | Total |
|---|---|---|---|
| Mean | 69.0 ± 12.1 | 70.1 ± 10.9 | 69.6 ± 11.5 |
| Central retinal thickness (CRT) in the study eye(μm) | Aflibercept Extended Dosing | Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) | Total |
|---|---|---|---|
| Mean | 257.3 ± 67.8 | 264.4 ± 59.7 | 260.9 ± 63.8 |
| Choroidal neovascularization (CNV) area in the study eye(mm*2) | Aflibercept Extended Dosing | Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) | Total |
|---|---|---|---|
| Mean | 4.695 ± 4.043 | 5.060 ± 4.105 | 4.875 ± 4.070 |
| Total score for National Eye Institute 25-Item Visual Function(Score on a scale) | Aflibercept Extended Dosing | Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) | Total |
|---|---|---|---|
| Mean | 72.889 ± 18.414 | 75.757 ± 15.495 | 74.340 ± 17.034 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Ran from Sep 2015 to primary completion in Dec 2019, 50 months.
Results were first posted in Apr 2021, 1 year 3 months after primary completion.
Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 50 months is above that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept